Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026

As the 2026 ESMO Congress gets underway, we’re preparing to see several potentially practice-informing gynecologic cancer presentations spanning advanced or recurrent and newly diagnosed endometrial cancer, as well as ovarian cancer. Several abstracts will explore key questions surrounding antibody-drug conjugates (ADCs) in recurrent disease, chemotherapy-free first-line treatment with immunotherapy, and the addition of immunotherapy to radiation in early-stage disease.

We polled our followers on social media about their opinions on some of the most talked-about gynecologic cancer abstracts they’re looking forward to seeing at this year’s meeting.

To read more about these studies and additional abstracts of interest ahead of ESMO 2026, read our in-depth preview.

Poll: Which gynecologic oncology abstract are you most excited to see data from at ESMO 2026?

• TroFuse-005
• KEYNOTE-C93
• NRG-GY020

Among the most anticipated presentations is LBA11, which will feature results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial (NCT06132958) of sacituzumab tirumotecan (MK-2870), a TROP2-directed ADC with a topoisomerase payload, vs chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. A May 2026 news release indicated that the trial met its dual primary end points of progression-free survival (PFS) and overall survival in certain patients.¹ Experts are looking to the data to clarify which patients benefited most, including by prior lines of therapy, histology, mismatch repair status, and prior checkpoint inhibitor use.

Abstract LBA12 will present findings from the phase 3 KEYNOTE-C93/GOG-3064/ENGOT-en15 trial (NCT05173987), which randomly assigned patients with mismatch repair–deficient (dMMR) advanced or recurrent endometrial carcinoma to receive first-line pembrolizumab (Keytruda) or carboplatin plus paclitaxel. A July 2026 news release indicated that pembrolizumab monotherapy significantly improved PFS vs chemotherapy in certain patients.² The data may help answer whether chemotherapy can be omitted in the first-line setting for patients with dMMR disease, and experts will be looking at the magnitude of benefit relative to historical trials of carboplatin plus paclitaxel with immunotherapy, as the control arm did not include immunotherapy.

Abstract 1239O will highlight data from the phase 3 NRG-GY020 trial (NCT04214067) of radiation with or without pembrolizumab in patients with newly diagnosed, early-stage, high-intermediate–risk dMMR endometrioid endometrial cancer. Previously, the phase 3 KEYNOTE-B21 trial (NCT04634877), which added pembrolizumab to adjuvant chemotherapy, did not report an improvement disease-free survival with this approach vs placebo plus chemotherapy in the all-comer population of patients with newly diagnosed, high-risk endometrial cancer.³ NRG-GY020 instead adds immunotherapy to radiation alone in a patient population restricted to those with dMMR disease, and the results may clarify whether immunotherapy can reduce recurrence in a setting where many patients experience good efficacy outcomes without additional systemic therapy.⁴

On LinkedIn, respondents (n = 11) favored KEYNOTE-C93 (72%), followed by TroFuse-005 (27%). Results were similar on X, with respondents (n = 8) favoring KEYNOTE-C93 (62.5%), followed by TroFuse-005 (37.5%).

Poll: Which gynecologic oncology subtype are you most interested in learning more about during the 2026 ESMO Congress?

• Ovarian cancer
• Endometrial cancer
• Cervical cancer

Beyond the above abstracts, ESMO 2026 will highlight updated results with ADCs in platinum-resistant ovarian cancer, including from the phase 1/2a FONTANA trial (NCT05797168) of the folate receptor α–targeted ADC torvutatug samrotecan (AZD5335) and the phase 1 BEHOLD-1 study (NCT06431594) of mocertatug rezetecan (HS-20089). Data are also expected with the CDK2 inhibitor INCB123667 plus bevacizumab (Avastin) from a phase 1 trial (NCT05238922) and with the WEE1 inhibitor azenosertib (ZN-c3) from the phase 2 DENALI trial (NCT05128825); these novel agents may play a role in the ovarian cancer treatment paradigm after patients progress on ADCs.

On LinkedIn, respondents (n = 20) favored ovarian cancer (65%), followed by endometrial cancer (20%) and cervical cancer (15%). On X, all respondents (n = 2) favored endometrial cancer (100%).

Collectively, these presentations reinforce the rapid pace of therapeutic evolution across gynecologic cancer subtypes. From novel ADCs to chemotherapy-sparing immunotherapy strategies, ESMO 2026 is expected to generate data that could shape future standards of care.

References

1. Merck announces TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met primary endpoints of overall survival (OS) and progression-free survival (PFS) in certain patients with advanced or recurrent endometrial cancer. News release. Merck. May 18, 2026. Accessed October 23, 2026. https://www.merck.com/news/merck-announces-trofuse-005-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-endpoints-of-overall-survival-os-and-progression-free-survival-pfs-in-certain-patients-with-advanced-or-r/
2. Keytruda (pembrolizumab) as monotherapy significantly improved progression-free survival (PFS) in certain patients with advanced or recurrent endometrial cancer with mismatch repair deficient (dMMR) tumors compared to chemotherapy. News release. Merck. July 15, 2026. Accessed October 23, 2026. https://www.merck.com/news/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-survival-pfs-in-certain-patients-with-advanced-or-recurrent-endometrial-cancer-with-mismatch-repair-deficient-d/
3. Van Gorp T, Cibula D, Lv W, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024;35(11):968-980. doi:10.1016/j.annonc.2024.08.2242
4. Testing the addition of the immunotherapy drug, pembrolizumab, to the usual radiation treatment for newly diagnosed early stage high intermediate risk endometrial cancer. ClinicalTrials.gov. Updated July 2, 2026. Accessed October 23, 2026. https://clinicaltrials.gov/study/NCT04214067